# Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

> **NCT03189537** · PHASE3 · COMPLETED · sponsor: **Valenta Pharm JSC** · enrollment: 400 (actual)

## Conditions studied

- Influenza, Human
- Acute Respiratory Infection
- Common Cold
- Flu
- Viral Infection

## Interventions

- **DRUG:** Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03189537
- **Lead sponsor:** Valenta Pharm JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-03
- **Primary completion:** 2011-04-19
- **Final completion:** 2011-10-10
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2017-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189537, "Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03189537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*